DelveInsight’s, “Adrenocortical Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenocortical Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook

Key Takeaways from the Adrenocortical Carcinoma Pipeline Report

• In May 2025, Corcept Therapeutics conducted a study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
• DelveInsight’s Adrenocortical Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment.
• The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
• Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.

Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs

Adrenocortical Carcinoma Emerging Drugs Profile

• Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body’s other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer.

• Ipilimumab: Bristol-Myers Squibb

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma.

The Adrenocortical Carcinoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
• Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market

Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Adrenocortical Carcinoma Drugs

Adrenocortical Carcinoma Companies

Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Adrenocortical Carcinoma Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers

Scope of the Adrenocortical Carcinoma Market Report

• Coverage- Global
• Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
• Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
• Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Adrenocortical Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Adrenocortical Carcinoma– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Ipilimumab: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. Relacorilant: Corcept Therapeutics
12. Preclinical and Discovery Stage Products
13. Drug name: Company name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Adrenocortical Carcinoma Key Companies
17. Adrenocortical Carcinoma Key Products
18. Adrenocortical Carcinoma- Unmet Needs
19. Adrenocortical Carcinoma- Market Drivers and Barriers
20. Adrenocortical Carcinoma- Future Perspectives and Conclusion
21. Adrenocortical Carcinoma Analyst Views
22. Adrenocortical Carcinoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adrenocortical-carcinoma-pipeline-insight